BIIB033

DRUG4 trials

Sponsors

Biogen

Conditions

Central Nervous System (CNS) Demyelinating DiseaseHealthyMultiple SclerosisRelapsing-Remitting Multiple Sclerosis

Phase 1

BIIB033 Single Ascending Dose Study in Healthy Volunteer Subjects

CompletedNCT01052506

Start: 2010-01-31End: 2011-10-31Updated: 2017-01-09

Safety Study of BIIB033 in Subjects With Multiple Sclerosis

CompletedNCT01244139

BiogenMultiple Sclerosis, Relapsing-Remitting Multiple Sclerosis

Start: 2010-10-31End: 2012-04-30Updated: 2017-01-09

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants

CompletedNCT02641041

BiogenCentral Nervous System (CNS) Demyelinating Disease, Multiple Sclerosis

Start: 2016-02-29End: 2016-09-30Updated: 2016-10-10

Phase 2

Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex

CompletedNCT01864148

BiogenMultiple Sclerosis

Start: 2013-08-31End: 2016-03-31Updated: 2017-05-03

Related Papers

Abnormalities in normal-appearing white matter from which multiple sclerosis lesions arise

Brain Communications2021-01-0128 citations

Patterning Chronic Active Demyelination in Slowly Expanding/Evolving White Matter MS Lesions.

2020-08-2035 citations

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.

2019-07-05137 citations

Additional Efficacy Analyses from the Phase 2b SYNERGY Study Investigating the Anti-LINGO-1 Monoclonal Antibody Opicinumab for Treatment of Disabling Multiple Sclerosis (P5.337)

Neurology2017-04-181 citations

Development of a Sensitive Outcome for Economical Drug Screening for Progressive Multiple Sclerosis Treatment

Frontiers in Neurology2016-08-1555 citations